Aug 1 |
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
|
Aug 1 |
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
|
Jul 31 |
Zymeworks Q2 2024 Earnings Preview
|
Jul 25 |
Zymeworks names Leone Patterson as chief business and financial officer
|
Jul 25 |
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
|
Jul 22 |
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
|
Jul 11 |
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
|
Jul 9 |
Zymeworks: A Somewhat Complicated Story
|
Jun 17 |
Zymeworks ZW171 IND for mesothelin-expressing cancers cleared by FDA
|
Jun 17 |
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
|